Business, energy, technology, markets and global industry news from Business News Today

lipid nanoparticles

PharmaDeviceNews lipid nanoparticles
Pharma & Biotech

Why Cartesian Therapeutics’ WestGene pact could intensify the race for autoimmune cell therapy

Find out how Cartesian Therapeutics’ WestGene deal could reshape in vivo CAR-T strategy in autoimmune disease and what risks remain.

Read More
Representative image of researchers working in a modern cell therapy laboratory, reflecting T-CURX’s acquisition of Pantherna Therapeutics and the growing race to advance in vivo CAR-T, mRNA delivery and lipid nanoparticle technologies.
Pharma & Biotech

Why T-CURX’s Pantherna acquisition could matter for the future of cell therapy manufacturing

T-CURX and Pantherna are combining CAR-T, mRNA and LNP platforms. Europe’s in vivo cell therapy race just became more serious.

Read More
Representative image showing cardiovascular drug research and epigenetic silencing technology, reflecting Scribe Therapeutics’ STX-1150 strategy for long-lasting LDL-C reduction after a single dose.
Pharma & Biotech

Can Scribe Therapeutics make one-dose LDL-C lowering a practical CRISPR frontier?

Find out how Scribe Therapeutics’ STX-1150 could reshape long-acting LDL-C lowering through CRISPR-based epigenetic silencing.

Read More
Pharma & Biotech

Can United Immunity revive macrophage cell therapy after Carisma’s reset?

Macrophage cell therapy has promise but painful execution risk. United Immunity’s Carisma deal tests whether in vivo CAR-M can scale.

Read More
Representative image: Scientists review DNA delivery and lipid nanoparticle research in a genetic medicines lab as Eli Lilly’s Engage Bio acquisition highlights the growing race to solve non-viral drug delivery challenges.
Pharma & Biotech

Eli Lilly expands genetic medicines toolkit with Engage Bio’s non-viral DNA delivery system

Eli Lilly’s Engage Bio deal is small by its standards, but DNA delivery may become a big battleground in genetic medicines.

Read More
Representative image of non-viral gene therapy research, showing how lipid nanoparticles, CRISPR-based editing and advanced delivery platforms are gaining attention as viral vector safety concerns reshape genetic medicine.
Features & Analysis

Can non-viral gene therapies solve the safety problem holding back genetic medicine?

Viral vectors built gene therapy’s first era. Safety, redosing and manufacturing pressure are pushing non-viral platforms into the spotlight.

Read More
Pharma & Biotech

How CPTx is positioning targeted lipid nanoparticles at the center of CAR T innovation

Explore how CPTx’s targeted lipid nanoparticle platform could reshape CAR T therapy scalability and access. Read the full analysis now.

Read More
Pharma & Biotech

What Lilly’s Orna Therapeutics deal means for immune reset strategies

Eli Lilly and Company has entered into a definitive agreement to acquire Orna Therapeutics, Inc., gaining access to the biotechnology firm’s circular RNA platform and its clinical trial ready in vivo CAR-T candidate ORN-252 targeting CD19 for B cell driven autoimmune diseases. The deal, valued at up to 2.4 billion dollars in cash including milestone

Read More